OncLive
OncLive, Plainsboro, NJ. 16K likes. OncLive covers every angle of your oncology practice, from new technology to treatment advances to important regulatory decisions
OncLive, Plainsboro, NJ. 16K likes. OncLive covers every angle of your oncology practice, from new technology to treatment advances to important regulatory decisions
European Respiratory Society. 36,086 likes · 245 talking about this. With members in over 100 countries, the European Respiratory Society (ERS) aims to alleviate sufferi
Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.
The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that…
Initial antitumor activity and safety data have been observed in the phase 1 portion of a phase 1/2a trial of IMM-1-104 in RAS-mutant solid tumors.
Patients with relapsed/refractory chronic lymphocytic leukemia experienced long-lasting responses with venetoclax.
Prolonged duration from neoadjuvant SCRT to surgery did not increase the risk of poor mesorectum specimen quality or post-operative morbidity in rectal cancer.
Francine Brinkhuis, MSc, and Lourens T. Bloem, PharmD, MSc, highlight findings from an analysis of the benefit and revenue for EU-approved oncology drugs.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.
Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.